Specific Use-Result of Spiriva Respimat® in Asthmatics

Boehringer Ingelheim

Status: Completed

Conditions: Asthma

Treatments: Drug: Spiriva Respimat

Study type: Observational

Funder types: Industry

Identifiers

NCT03188120

0205-0536

Details and patient eligibility

About

The study objective is to investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use

Full description

The study is Post-Marketing Surveillance on the Long-Term Use of Spiriva Respimat in Japanese patients with mild to moderate persistent asthma. The patient population who receive Spiriva Respimat and the safety profile is not expected to change. This study can investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use

Enrollment: 193 patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with mild to moderate persistent bronchial asthma
• Patient aged ≥ 15 years
• Patients who are naive to Spiriva Respimat and receive Spiriva Respimat for the first time for treatment of bronchial asthma on top of at least ICS treatment.

Exclusion criteria

• Patients who have a contraindication to Spiriva Respimat defined in the package insert for Spiriva Respimat
• Patients who have been enrolled in this study before.

Trial design

193 participants in 1 patient group

Spiriva Respimat group

Treatment:

Drug: Spiriva Respimat